Robotics' IPO Pipeline: Who's Actually Ready logo

Robotics' IPO Pipeline: Who's Actually Ready

Figure AI at a private $39B valuation and China's Unitree pursuing a Shanghai STAR Market listing represent two very different paths to a robotics IPO -- and neither looks genuinely ready by the disclosure standards Cerebras and SpaceX have just set.

By the Numbers

$39B private
Figure AI valuation
Shanghai STAR Market
Unitree path
TC
By the IPO Desk
Edited by Trace Cohen · Early-stage VC & angel · Founder, New York Venture Partners
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Figure AI, the best-funded pure-play humanoid robotics company at a $39B private valuation, has given no public IPO timeline

2

Unitree is pursuing a Shanghai STAR Market listing, following a different regulatory and disclosure path than a US Nasdaq listing would require

3

Neither company has disclosed the kind of unit economics or customer concentration data that public markets have started demanding from AI-infrastructure IPOs this year

4

The eventual first pure-play humanoid robotics IPO will face the same comp-vacuum problem as nuclear and chip challengers -- there's no existing public robotics company built around this exact business model

TC

The VC Read · Trace's Take

Trace Cohen

A $39B private valuation with zero disclosed unit economics is exactly the kind of number that looks great in a pitch deck and terrifying in an S-1. Figure and Unitree are both real businesses with real production data behind closed doors -- the question is whether either team is willing to open that data up before the market forces them to at IPO, which is always the harder and more credible path.

Analysis

Humanoid robotics has produced some of 2026's biggest private valuations, but a close look at the two most likely IPO candidates shows neither is close to ready by the disclosure standard the market has started demanding from other AI-infrastructure listings this year. Figure AI, the best-funded pure-play humanoid company at a $39 billion private valuation, has given no public IPO timeline. Unitree is pursuing a different path entirely, working toward a Shanghai STAR Market listing rather than a US exchange, which carries its own regulatory and disclosure framework distinct from what Cerebras or SpaceX had to meet on Nasdaq.

Two Different Paths, Neither Ready

Neither company has published the kind of unit economics -- production cost per robot, customer concentration, utilization rates -- that public investors have started explicitly demanding from AI-infrastructure IPOs since Cerebras's listing. That's a real gap: the manufacturing data available on humanoid robotics right now (Figure's roughly 1,000 cumulative units, AgiBot's 15,000) shows real production activity, but nothing close to the disclosure granularity a US public listing would require.

The eventual first pure-play humanoid robotics IPO, whenever it comes, will face the same structural problem as the nuclear and chip challengers: there's no existing public company built around this exact business model to price against. Industrial robotics comps (Fanuc, ABB) don't map cleanly onto AI-driven humanoid platforms, and the closest analog -- Tesla's Optimus program -- isn't a standalone public entity investors can benchmark against directly.

The US-China split adds a further wrinkle: Figure and Unitree represent the two dominant national approaches to humanoid manufacturing, and if they eventually list on different exchanges under different disclosure regimes, investors will be comparing companies that were never required to report the same operating metrics in the first place.

What to watch: whether either company begins disclosing production-cost or utilization data voluntarily ahead of any formal IPO process, which would be the clearest early signal of genuine listing readiness rather than just valuation momentum.

ShareXLinkedInEmail

Key Sources

2 sources

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.